These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29031230)

  • 1. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
    Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
    Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
    Feng Y; Zhou Z; McDougald D; Meshaw RL; Vaidyanathan G; Zalutsky MR
    Nucl Med Biol; 2021 Jan; 92():171-183. PubMed ID: 32448731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose
    Feng Y; Meshaw R; Zhao XG; Jannetti S; Vaidyanathan G; Zalutsky MR
    J Nucl Med; 2023 Jan; 64(1):124-130. PubMed ID: 35618478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
    Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
    Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Labeling single domain antibody fragments with
    Zhou Z; McDougald D; Meshaw R; Balyasnikova I; Zalutsky MR; Vaidyanathan G
    Nucl Med Biol; 2021; 100-101():24-35. PubMed ID: 34146837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics.
    Huynh TT; Feng Y; Meshaw R; Zhao XG; Rosenfeld L; Vaidyanathan G; Papo N; Zalutsky MR
    Nucl Med Biol; 2024; 134-135():108913. PubMed ID: 38703588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-Specific and Residualizing Linker for
    Zhou Z; Meshaw R; Zalutsky MR; Vaidyanathan G
    J Nucl Med; 2021 Nov; 62(11):1624-1630. PubMed ID: 33637584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
    Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labeling a TCO-functionalized single domain antibody fragment with
    Zhou Z; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
    Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
    Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
    Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
    Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.
    Choi J; Vaidyanathan G; Koumarianou E; McDougald D; Pruszynski M; Osada T; Lahoutte T; Lyerly HK; Zalutsky MR
    Nucl Med Biol; 2014; 41(10):802-12. PubMed ID: 25156548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of an
    Feng Y; Meshaw R; McDougald D; Zhou Z; Zhao XG; Jannetti SA; Reiman RE; Pippen E; Marjoram R; Schaal JL; Vaidyanathan G; Zalutsky MR
    Sci Rep; 2022 Feb; 12(1):3020. PubMed ID: 35194100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent.
    Feng Y; Sarrett SM; Meshaw RL; Vaidyanathan G; Cornejo MA; Zeglis BM; Zalutsky MR
    J Med Chem; 2022 Nov; 65(22):15358-15373. PubMed ID: 36368007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution.
    Pruszynski M; Kang CM; Koumarianou E; Vaidyanathan G; Zalutsky MR
    Molecules; 2018 May; 23(5):. PubMed ID: 29783774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
    Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
    Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At.
    Vaidyanathan G; Affleck DJ; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2003 May; 30(4):351-9. PubMed ID: 12767391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.